New Biomarker Panel for Colorectal Cancer Detection
Author Information
Author(s): Lind Guro E, Danielsen Stine A, Ahlquist Terje, Merok Marianne A, Andresen Kim, Skotheim Rolf I, Hektoen Merete, Rognum Torleiv O, Meling Gunn I, Hoff Geir, Bretthauer Michael, Thiis-Evensen Espen, Nesbakken Arild, Lothe Ragnhild A
Primary Institution: Oslo University Hospital
Hypothesis
Can a panel of epigenetic biomarkers improve the detection of colorectal cancer and adenomas?
Conclusion
The novel epigenetic marker panel shows very high sensitivity and specificity for both colorectal cancers and adenomas.
Supporting Evidence
- Promoter hypermethylation of specific genes was frequent in colorectal cancers and adenomas.
- The combined sensitivity of at least two positives among the six markers was 94% for colorectal cancers and 93% for adenomas.
- The specificity of the biomarker panel was 98%.
- ROC curve analysis showed high accuracy for the biomarker panel in distinguishing cancers and adenomas from normal mucosa.
Takeaway
Scientists found a way to detect colorectal cancer and its early signs using a special test that looks for changes in DNA from stool samples.
Methodology
The study analyzed DNA methylation patterns in tissue samples from colorectal cancers, adenomas, and normal colonic mucosa using quantitative methylation analysis and ROC curve analysis.
Potential Biases
Potential bias in sample selection and analysis methods could affect the results.
Limitations
The study may not account for all potential confounding factors in the detection of colorectal cancer.
Participant Demographics
The median age of colorectal cancer patients was 71 years, and for adenoma patients, it was 67 years.
Statistical Information
P-Value
p<0.0001
Confidence Interval
Not specified
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website